Notis McConarty Edward Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)

Notis McConarty Edward cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% in the 4th quarter, HoldingsChannel reports. The fund owned 37,203 shares of the company’s stock after selling 1,194 shares during the quarter. Johnson & Johnson accounts for 2.6% of Notis McConarty Edward’s portfolio, making the stock its 14th biggest position. Notis McConarty Edward’s holdings in Johnson & Johnson were worth $5,380,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of JNJ. Oregon Pacific Wealth Management LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at $949,000. Horan Securities Inc. boosted its holdings in shares of Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after purchasing an additional 90 shares during the period. Strategic Financial Concepts LLC grew its stake in shares of Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after purchasing an additional 1,271 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $69,859,000. Finally, KPP Advisory Services LLC raised its position in Johnson & Johnson by 4.7% during the 4th quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock valued at $1,662,000 after purchasing an additional 515 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on JNJ shares. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday. Wells Fargo & Company reduced their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Bank of America raised their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 5th. Stifel Nicolaus decreased their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Finally, Barclays raised their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Stock Down 4.3 %

NYSE:JNJ opened at $153.03 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market cap of $368.77 billion, a P/E ratio of 23.01, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a 50-day simple moving average of $159.75 and a two-hundred day simple moving average of $155.91.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the business earned $2.29 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.